SG11201909710XA - Indole ahr inhibitors and uses thereof - Google Patents
Indole ahr inhibitors and uses thereofInfo
- Publication number
- SG11201909710XA SG11201909710XA SG11201909710XA SG11201909710XA SG 11201909710X A SG11201909710X A SG 11201909710XA SG 11201909710X A SG11201909710X A SG 11201909710XA SG 11201909710X A SG11201909710X A SG 11201909710XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- april
- pct
- publication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488476P | 2017-04-21 | 2017-04-21 | |
| US201762592542P | 2017-11-30 | 2017-11-30 | |
| US201862658454P | 2018-04-16 | 2018-04-16 | |
| PCT/US2018/028532 WO2018195397A2 (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909710XA true SG11201909710XA (en) | 2019-11-28 |
Family
ID=63856153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909710X SG11201909710XA (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10570138B2 (es) |
| EP (1) | EP3612030A4 (es) |
| JP (2) | JP7232244B2 (es) |
| KR (1) | KR20190141722A (es) |
| CN (1) | CN110831600B (es) |
| AU (1) | AU2018256459B2 (es) |
| BR (1) | BR112019021992A2 (es) |
| CA (1) | CA3059939A1 (es) |
| CL (1) | CL2019003015A1 (es) |
| CO (1) | CO2019011584A2 (es) |
| IL (1) | IL270025B2 (es) |
| MX (1) | MX2019012431A (es) |
| SG (1) | SG11201909710XA (es) |
| TW (1) | TWI778050B (es) |
| WO (1) | WO2018195397A2 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017377069B2 (en) | 2016-12-16 | 2020-07-23 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| JP7232244B2 (ja) | 2017-04-21 | 2023-03-08 | イケナ オンコロジー， インコーポレイテッド | インドールａｈｒ阻害剤およびその使用 |
| FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| WO2019036657A1 (en) | 2017-08-17 | 2019-02-21 | Kyn Therapeutics | AHR INHIBITORS AND USES THEREOF |
| EP4219495A1 (en) | 2018-02-06 | 2023-08-02 | Ideaya Biosciences, Inc. | Ahr modulators |
| WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| KR20210056373A (ko) * | 2018-09-07 | 2021-05-18 | 오츠카 세이야쿠 가부시키가이샤 | 헤테로시클릭 화합물 |
| CN113272305A (zh) * | 2018-10-16 | 2021-08-17 | 医肯纳肿瘤学公司 | 吲哚ahr抑制剂及其用途 |
| US20210379033A1 (en) * | 2018-10-17 | 2021-12-09 | Magenta Therapeutics Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
| CN113454076A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用于激活造血干细胞和祖细胞的芳香族化合物 |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| US20220233531A1 (en) * | 2019-02-27 | 2022-07-28 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
| US20220281824A1 (en) * | 2019-07-30 | 2022-09-08 | Oregon State University | Aryl hydrocarbon receptor activators |
| US20230295152A1 (en) * | 2019-11-22 | 2023-09-21 | Senda Biosciences, Inc. | Pyridopyrimidinone derivatives as ahr antagonists |
| WO2021108528A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| US20230026232A1 (en) | 2019-11-26 | 2023-01-26 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| BR112022009856A2 (pt) * | 2019-11-26 | 2022-08-02 | Hoffmann La Roche | Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune |
| TW202146416A (zh) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
| CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| WO2021173082A1 (en) | 2020-02-26 | 2021-09-02 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| KR20230005844A (ko) * | 2020-03-27 | 2023-01-10 | 동아에스티 주식회사 | 아미노피리미딘 유도체 및 이의 아릴 탄화수소 수용체 조절제로서의 용도 |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2022029063A1 (en) * | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| MX2023004847A (es) | 2020-10-28 | 2023-07-11 | Ikena Oncology Inc | Combinación de un inhibidor del receptor de hidrocarburos de arilo (ahr) con un inhibidor de pdx o doxorrubicina. |
| CN114644627A (zh) * | 2020-12-18 | 2022-06-21 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
| CN112656789A (zh) * | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Ficz在抑制肿瘤细胞迁移中的应用 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| WO2023020512A1 (zh) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | 取代的吡啶类似物、其制备方法及作为ahr调节剂的用途 |
| WO2023033740A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115093400B (zh) * | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂及其用途和制备方法 |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN115925684A (zh) * | 2021-12-03 | 2023-04-07 | 徐诺药业(南京)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
| WO2023135057A1 (en) | 2022-01-11 | 2023-07-20 | Deutsches Krebsforschungszentrum | Bicyclic triazine derivatives for the treatment of cancer |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115804776A (zh) * | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | 一种芳香烃受体抑制剂和5-氟尿嘧啶合用在治疗抑制肿瘤药物中的应用 |
| CN116482278B (zh) * | 2023-05-06 | 2024-02-09 | 广州清瑞生物科技有限责任公司 | 一种用于检测阿昔洛韦的对照品的制备方法 |
| CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| HUP0303315A2 (hu) * | 2000-12-19 | 2004-01-28 | Merck Patent Gmbh. | Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények |
| EP1426046A4 (en) | 2001-09-14 | 2005-11-02 | Shionogi & Co | NEW USE OF TRICYCLIC COMPOUNDS |
| ES2285164T3 (es) * | 2002-09-04 | 2007-11-16 | Schering Corporation | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina. |
| AR041291A1 (es) * | 2002-09-19 | 2005-05-11 | Schering Corp | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR20070118068A (ko) * | 2004-11-23 | 2007-12-13 | 레디 유에스 테라퓨틱스 인코포레이티드 | 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물 |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| EP1879573B1 (en) | 2005-05-10 | 2012-12-19 | Incyte Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| JP5252635B2 (ja) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | プログラム死リガンド１（ｐｄ−ｌ１）に対するヒトモノクローナル抗体 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5357763B2 (ja) | 2006-11-06 | 2013-12-04 | トレロ ファーマシューティカルズ， インコーポレイテッド | イミダゾ［１，２−ｂ］ピリダジン誘導体およびピラゾロ［１，５−ａ］ピリダジン誘導体およびプロテインキナーゼインヒビターとしてのこれらの使用 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| CN101952283B (zh) * | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物 |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| LT4209510T (lt) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antikūnai ir jų panaudojimas t ląstelių funkcijos pagerinimui |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
| RS58693B1 (sr) | 2009-12-10 | 2019-06-28 | Hoffmann La Roche | Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| TWI713942B (zh) | 2010-05-04 | 2020-12-21 | 美商戊瑞治療有限公司 | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 |
| SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
| US8957077B2 (en) * | 2010-09-30 | 2015-02-17 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE 10 inhibitors |
| JP5947311B2 (ja) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用 |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CN103492389B (zh) * | 2011-04-21 | 2016-09-14 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| WO2013086436A1 (en) * | 2011-12-08 | 2013-06-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| CA2871445C (en) | 2012-05-11 | 2020-07-07 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| CA3057159A1 (en) | 2017-04-12 | 2018-10-18 | Magenta Therapeutics Inc. | Aryl hydrocarbon receptor antagonists and uses thereof |
| JP7232244B2 (ja) | 2017-04-21 | 2023-03-08 | イケナ オンコロジー， インコーポレイテッド | インドールａｈｒ阻害剤およびその使用 |
-
2018
- 2018-04-20 JP JP2020507495A patent/JP7232244B2/ja active Active
- 2018-04-20 TW TW107113564A patent/TWI778050B/zh active
- 2018-04-20 WO PCT/US2018/028532 patent/WO2018195397A2/en active Application Filing
- 2018-04-20 US US15/958,586 patent/US10570138B2/en active Active
- 2018-04-20 CN CN201880038301.XA patent/CN110831600B/zh active Active
- 2018-04-20 SG SG11201909710X patent/SG11201909710XA/en unknown
- 2018-04-20 BR BR112019021992A patent/BR112019021992A2/pt unknown
- 2018-04-20 MX MX2019012431A patent/MX2019012431A/es unknown
- 2018-04-20 KR KR1020197034489A patent/KR20190141722A/ko active IP Right Grant
- 2018-04-20 AU AU2018256459A patent/AU2018256459B2/en active Active
- 2018-04-20 EP EP18787414.4A patent/EP3612030A4/en active Pending
- 2018-04-20 CA CA3059939A patent/CA3059939A1/en active Pending
-
2019
- 2019-10-17 IL IL270025A patent/IL270025B2/en unknown
- 2019-10-18 CO CONC2019/0011584A patent/CO2019011584A2/es unknown
- 2019-10-21 CL CL2019003015A patent/CL2019003015A1/es unknown
- 2019-10-30 US US16/668,070 patent/US10689388B1/en active Active
-
2020
- 2020-04-08 US US16/843,606 patent/US11358969B2/en active Active
-
2022
- 2022-05-06 US US17/662,246 patent/US20230028336A1/en active Pending
- 2022-06-06 JP JP2022091740A patent/JP2022116319A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018256459A1 (en) | 2019-11-07 |
| CN110831600A (zh) | 2020-02-21 |
| US20230028336A1 (en) | 2023-01-26 |
| IL270025B2 (en) | 2023-05-01 |
| BR112019021992A2 (pt) | 2020-06-09 |
| EP3612030A2 (en) | 2020-02-26 |
| US11358969B2 (en) | 2022-06-14 |
| JP2020517734A (ja) | 2020-06-18 |
| KR20190141722A (ko) | 2019-12-24 |
| US10689388B1 (en) | 2020-06-23 |
| JP2022116319A (ja) | 2022-08-09 |
| TW201841917A (zh) | 2018-12-01 |
| US20200331917A1 (en) | 2020-10-22 |
| WO2018195397A2 (en) | 2018-10-25 |
| CL2019003015A1 (es) | 2020-03-27 |
| IL270025B1 (en) | 2023-01-01 |
| IL270025A (es) | 2019-12-31 |
| JP7232244B2 (ja) | 2023-03-08 |
| TWI778050B (zh) | 2022-09-21 |
| CN110831600B (zh) | 2023-10-17 |
| MX2019012431A (es) | 2020-08-03 |
| WO2018195397A3 (en) | 2018-12-13 |
| CA3059939A1 (en) | 2018-10-25 |
| AU2018256459B2 (en) | 2023-12-07 |
| US20180327411A1 (en) | 2018-11-15 |
| EP3612030A4 (en) | 2021-04-28 |
| CO2019011584A2 (es) | 2020-02-18 |
| US10570138B2 (en) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808751SA (en) | T cell receptors | |
| SG11201811643TA (en) | Compounds and methods for modulating rna function | |
| SG11201903456WA (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound |